Oracle Drug Software Infringes Patent, Suit Says

Law360, New York (December 20, 2010, 1:38 PM EST) -- DrugLogic Inc. has accused Oracle Corp., which recently acquired two of DrugLogic's competitors in the market for drug safety surveillance software, of breaching a marketing agreement and infringing a patent for an online system that analyzes adverse drug effects.

The complaint, filed Friday in the U.S. District Court for the Northern District of California, targets products marketed by Oracle that had previously been made by the now-acquired competitors, Relsys International Inc. and Phase Forward Inc.

Oracle acquired Relsys in March 2009 and Phase Forward in April...
To view the full article, register now.